BTK and mantle cell lymphoma: To test this possibility, we used ibrutinib (PCI‐32765), an inhibitor that irreversibly binds to the C481 residue of BTK and inhibits Y223 stimulation and has been approved to treat mantle cell lymphoma and CLL (Aalipour & Advani, 2014).